Cisplatin tnbc
WebSep 22, 2010 · Cisplatin also promotes apoptosis in TNBC by disrupting a complex between the p53 family members ΔNp63 and TAp73 that is present selectively in TNBC with mutant TP53 . Specifically, cisplatin induces c-Abl-mediated phosphorylation of TAp73, which releases pro-apoptotic TAp73 from the inhibitory complex and triggers apoptosis. ... WebNational Center for Biotechnology Information
Cisplatin tnbc
Did you know?
WebJun 6, 2024 · Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of … WebJul 22, 2024 · Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side …
WebFeb 1, 2011 · The previous phase II study showed that gemcitabine and cisplatin combination (GP) is an effective regimen in triple negative breast cancer (TNBC). The potential therapeutic effects of GP in advanced TNBC deserve further evaluation yet. Eligible patients are randomly assigned to receive either GP or GT regimen to verify the … WebNov 8, 2024 · Background. Triple negative breast cancer (TNBC) represents 15–20% of breast cancers. Due to its heterogeneity and high rates of relapse, there is a need to …
WebMar 22, 2024 · In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin. Genetic testing was underutilized in ... WebJun 22, 2024 · Cisplatin (DDP) was reported to improve pathological complete response (pCR) rates in triple-negative breast cancer (TNBC) patients, however, the molecular mechanism still remains largely unknown. Emerging evidence suggested that some chemotherapeutic drugs played anti-tumor effects by inducing cell pyroptosis.
WebNov 4, 2024 · Cisplatin has been in use for over 40 years to treat multiple types of cancer. Substatial data correlating cisplatin sensitivity with respect to TNBC subtypes and …
WebJan 3, 2024 · Triple Negative Breast Cancer: Drug: Cisplatin Drug: Nab-paclitaxel Drug: Pembrolizumab Drug: Olaparib: Phase 2: Detailed Description: TNBC is a hard-to-treat disease requiring continuous administration of drugs, necessitating further exploration of optimal maintenance strategy. However, there are currently no standard maintenance … cynthia l piepenbrok edmonds waWebTriple-negative breast cancer (TNBC) is the most dangerous subtype with the worst therapeutic prognosis and outcomes due to the absence of receptors for estrogen, progesterone, and HER2. Chemotherapy is the standard treatment for TNBC, and cisplatin is widely used in the clinical management of TNBC [1–3]. Therefore, the loss of … bill zivic artworkWebOur result demonstrates the lack of TGF-β induced TMEPAI on the TNBC response to cisplatin. This might be due to the overexpression of Islet-1 in TNBC patients. 47 Islet-1 overexpression was reported to reduce TNBC cell response to cisplatin. 47,48 In the cells that have limited response to cisplatin, the role of TMEPAI is not prominent. billzo famous birthdaysWebCisplatin (DDP) was reported to improve pathological complete response (pCR) rates in triple-negative breast cancer (TNBC) patients, however, the molecular mechanism still remains largely unknown. Emerging evidence suggested that some chemotherapeutic drugs played anti-tumor effects by inducing cell pyroptosis. cynthia loyst photosWebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast cancer (TNBC) is the most invasive subtype with a relatively poor prognosis, because it lacks targeted therapies and has a low response to chemotherapy [3,4].Moreover, the disease … billzo and ranboo fanartWebOur result demonstrates the lack of TGF-β induced TMEPAI on the TNBC response to cisplatin. This might be due to the overexpression of Islet-1 in TNBC patients. 47 Islet-1 … billzo headbandWebApr 10, 2024 · Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10–20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and carboplatin are effective in TNBC patients, their toxicity and development of cancer drug resistance often hamper their clinical use. Hence, novel … bill zobel to tell the truth